RxDoctor Payments Data

Fran Webb

Physician Assistant · Thomasville, GANPI 1902397672

Payments from drug & device makers

$8,532in general payments, 2019–2025

Across 223 payments — averaging $38.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Axonics, Inc.$2K
  • Sumitomo Pharma America, Inc.$570
  • Astellas Pharma US Inc$389
  • Endo Pharmaceuticals Inc.$262
  • Procept Biorobotics Corporation$256
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$1171%
  • Travel & lodging$99412%
  • Food & beverage$7,25485%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,532 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$47,150
Medicare patients
236
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron71$35,606
MyrbetriqMirabegron44$24,934
Testosterone14$1,942
Tamsulosin Hcl183$1,486
CefuroximeCefuroxime Axetil61$681
Doxycycline Monohydrate32$437
Cephalexin12$360
Oxybutynin Chloride ErOxybutynin Chloride33$351
Alfuzosin Hcl ErAlfuzosin Hcl14$347
Gentamicin Sulfate37$334
Finasteride65$320
Solifenacin Succinate14$239
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$173
Venlafaxine Hcl ErVenlafaxine Hcl14$155
Doxycycline Hyclate11$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$570$35,60671 claims
Astellas Pharma US IncMyrbetriq$389$24,93444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →